These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19303268)

  • 1. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study.
    Gerdts E; Okin PM; Omvik P; Wachtell K; Dahlöf B; Hildebrandt P; Nieminen MS; Devereux RB
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):306-12. PubMed ID: 19303268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Li ZB; Wachtell K; Okin PM; Gerdts E; Liu JE; Nieminen MS; Jern S; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):397-402. PubMed ID: 15071485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Gerdts E; Okin PM; de Simone G; Cramariuc D; Wachtell K; Boman K; Devereux RB
    Hypertension; 2008 Apr; 51(4):1109-14. PubMed ID: 18259011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
    Gerdts E; Franklin S; Rieck A; Papademetriou V; Wachtell K; Nieminen M; Dahlöf B; Devereux RB
    Blood Press; 2009; 18(4):180-6. PubMed ID: 19562573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
    Wachtell K; Gerdts E; Palmieri V; Olsen MH; Nieminen MS; Papademetriou V; Boman K; Dahlöf B; Aurigemma GP; Rokkedal JE; Devereux RB
    J Hypertens; 2010 Jul; 28(7):1541-6. PubMed ID: 20410835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
    Mancusi C; Gerdts E; De Simone G; Abdelhai YM; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2014 Aug; 23(4):206-12. PubMed ID: 24564262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
    Gerdts E; Okin PM; Boman K; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
    Am J Hypertens; 2012 Jun; 25(6):678-83. PubMed ID: 22456225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
    Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
    Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Palmieri V; Okin PM; Bella JN; Wachtell K; Oikarinen L; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2006 Oct; 24(10):2079-84. PubMed ID: 16957569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
    Gerdts E; Zabalgoitia M; Björnstad H; Svendsen TL; Devereux RB
    Am J Cardiol; 2001 Apr; 87(8):980-3; A4. PubMed ID: 11305990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study).
    Zabalgoitia M; Rahman SN; Haley WE; Yarows S; Krause L; Anderson LC; Oraby MA; Amarena J
    Am J Cardiol; 2001 Sep; 88(5):521-5. PubMed ID: 11524061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.
    Muiesan ML; Salvetti M; Monteduro C; Rizzoni D; Corbellini C; Castellano M; Porteri E; Agabiti-Rosei E
    J Hypertens; 2000 Nov; 18(11):1651-6. PubMed ID: 11081779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study.
    Hildebrandt P; Wachtell K; Dahlöf B; Papademitriou V; Gerdts E; Giles T; Oikarinen L; Tuxen C; Olsen MH; Devereux RB
    Diabet Med; 2005 Aug; 22(8):1005-11. PubMed ID: 16026365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.